Kamada Ltd. Declares Annual Dividend of $0.17 (NASDAQ:KMDA)

Posted by Trevor Kearing on Aug 17th, 2026

Kamada Ltd. (NASDAQ:KMDA – Get Free Report) declared an annual dividend on Monday, August 17th. Shareholders of record on Thursday, August 27th will be paid a dividend of 0.17 per share by the biotechnology company on Thursday, September 17th. This represents a yield of 219.0%. The ex-dividend date is Thursday, August 27th.

Kamada has a dividend payout ratio of 46.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Kamada to earn $0.60 per share next year, which means the company should continue to be able to cover its $0.18 annual dividend with an expected future payout ratio of 30.0%.

Kamada Stock Performance

Shares of NASDAQ:KMDA traded up $0.18 during trading on Monday, hitting $7.76. The company’s stock had a trading volume of 353,565 shares, compared to its average volume of 64,856. Kamada has a fifty-two week low of $6.50 and a fifty-two week high of $9.35. The business has a 50 day moving average price of $7.22 and a two-hundred day moving average price of $7.96. The company has a market capitalization of $446.28 million, a PE ratio of 20.42, a P/E/G ratio of 0.67 and a beta of 0.86.

Kamada (NASDAQ:KMDA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.05. The business had revenue of $54.92 million for the quarter, compared to analysts’ expectations of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%. As a group, equities analysts expect that Kamada will post 0.45 earnings per share for the current fiscal year.

Kamada Company Profile

(Get Free Report)

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.